| A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma (NCT03395080) | Leap Therapeutics, Inc. | 2018-03-05 |
| Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer (NCT03225989) | Lokon Pharma AB | 2018-03-01 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| IMX-110 in Patients With Advanced Solid Tumors (NCT03382340) | Immix Biopharma Australia Pty Ltd | 2018-02-15 |
| Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients (NCT03342417) | ExcellaBio LLC | 2018-02-14 |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT03029403) | University Health Network, Toronto | 2018-02-12 |
| Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer (NCT04752865) | Hellenic Cooperative Oncology Group | 2018-02-09 |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK (NCT03287271) | Michael McHale | 2018-02-06 |
| QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer (NCT03164980) | North Eastern German Society of Gynaecological Oncology | 2018-02-01 |
| Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) (NCT03931304) | Hospices Civils de Lyon | 2018-02-01 |
| China Ovarian Cancer BRCA Testing Study (NCT03203993) | AstraZeneca | 2018-01-31 |
| OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer (NCT03180307) | On Target Laboratories, LLC | 2018-01-26 |
| Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian Cancer (NCT06458361) | Zhongda Hospital | 2018-01-01 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Shorter Scalp Cooling Time in Paclitaxel (NCT03266185) | Leiden University Medical Center | 2017-12-20 |
| Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients (NCT03321188) | Andrea Jewell | 2017-12-15 |
| Phase Ib Study of Chiauranib in Patients With Ovarian Cancer (NCT03166891) | Chipscreen Biosciences, Ltd. | 2017-12-15 |
| Decision Support for BRCA Testing in Ethnically Diverse Women (NCT03470402) | Columbia University | 2017-12-13 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer (NCT03858166) | Shandong University | 2017-12-01 |
| Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients (NCT03863912) | Medical University of Vienna | 2017-12-01 |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (NCT03197584) | ImmunityBio, Inc. | 2017-12-01 |
| Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire (NCT03614689) | Geneplus-Beijing Co. Ltd. | 2017-11-25 |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (NCT03314935) | Incyte Corporation | 2017-11-21 |
| Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (NCT03326713) | Rutgers, The State University of New Jersey | 2017-11-02 |
| Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation. (NCT05458973) | Yonsei University | 2017-10-31 |
| Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer (NCT03448354) | Ajou University School of Medicine | 2017-10-26 |
| The Treatment Preferences of Women Diagnosed With Ovarian Cancer (NCT03367260) | Duke University | 2017-10-19 |
| Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (NCT03249142) | ARCAGY/ GINECO GROUP | 2017-10-18 |
| Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer (NCT03298074) | Yang Zhijun | 2017-10-01 |
| Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients (NCT03032614) | The University of Texas Health Science Center at San Antonio | 2017-09-30 |
| Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer (NCT03371693) | Zhongnan Hospital | 2017-09-30 |
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer (NCT03146663) | NuCana plc | 2017-09-28 |
| A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies (NCT02963831) | Ludwig Institute for Cancer Research | 2017-09-07 |
| Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer (NCT03367182) | Yonsei University | 2017-09-01 |
| Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy (NCT03206645) | University of Oklahoma | 2017-08-28 |
| A Study of IMP4297 in Patients With Advanced Solid Tumors (NCT03508011) | Impact Therapeutics, Inc. | 2017-08-23 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies (NCT03323398) | ModernaTX, Inc. | 2017-08-15 |
| Liquid Biopsy Evaluation and Repository Development at Princess Margaret (NCT03702309) | University Health Network, Toronto | 2017-08-03 |
| Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer (NCT04337632) | Hunan Cancer Hospital | 2017-08-01 |
| Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics (NCT04032600) | Charite University, Berlin, Germany | 2017-08-01 |
| A Study of Apatinib Treatment in for Advanced Ovarian Cancer (NCT03393507) | The People's Hospital of Leshan | 2017-08-01 |
| Real-life Use of Niraparib in a Patient Access Program in Norway (NCT04785716) | Kristina Lindemann | 2017-07-31 |
| Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast (NCT03154281) | Avera McKennan Hospital & University Health Center | 2017-07-26 |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer (NCT02978222) | Marker Therapeutics, Inc. | 2017-07-20 |
| EDMONd - Elemental Diet in Bowel Obstruction (NCT03150992) | Royal Surrey County Hospital NHS Foundation Trust | 2017-07-19 |
| Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region (NCT03082976) | AstraZeneca | 2017-07-16 |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (NCT03188159) | National University Hospital, Singapore | 2017-07-01 |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas (NCT03205176) | AstraZeneca | 2017-06-30 |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer (NCT03127098) | NantCell, Inc. | 2017-06-26 |
| Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer (NCT03056833) | Ronald Buckanovich | 2017-06-10 |
| Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer (NCT03235648) | Mansoura University | 2017-06-01 |
| Hysterectomy and OPPortunistic SAlpingectomy (NCT03045965) | Göteborg University | 2017-06-01 |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (NCT03149549) | CytomX Therapeutics | 2017-06-01 |
| A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (NCT03073525) | Gradalis, Inc. | 2017-05-31 |
| Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (NCT02855697) | The Christie NHS Foundation Trust | 2017-05-26 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies (NCT03144661) | Incyte Corporation | 2017-05-25 |
| Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors (NCT03189108) | National Cancer Institute (NCI) | 2017-05-22 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| A Study of SY-1365 in Adult Patients With Advanced Solid Tumors (NCT03134638) | Syros Pharmaceuticals | 2017-05-12 |
| Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers (NCT03162289) | Charite University, Berlin, Germany | 2017-05-10 |
| Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer (NCT03691012) | Walter and Eliza Hall Institute of Medical Research | 2017-05-09 |
| Effectiveness of Care in Certified Cancer Centres in Germany (NCT04334239) | Technische Universität Dresden | 2017-05-01 |
| CAR T Cells in Mesothelin Expressing Cancers (NCT03054298) | University of Pennsylvania | 2017-04-06 |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (NCT02830724) | National Cancer Institute (NCI) | 2017-04-06 |
| A Phase I Clinical Trial of Bevacizumab Injection (NCT05476341) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-04-06 |
| A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer (NCT03069872) | University of Aarhus | 2017-04-05 |
| Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 (NCT03004391) | Vejle Hospital | 2017-04-01 |
| Evolution of the Therapeutic Care in Ovarian Cancer From 2011 (NCT03275298) | UNICANCER | 2017-04-01 |
| An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer (NCT03446495) | Suriya Yessentayeva | 2017-03-28 |
| Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (NCT03159572) | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2017-03-28 |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients (NCT03075462) | Jiangsu HengRui Medicine Co., Ltd. | 2017-03-09 |
| Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT03117933) | University of Oxford | 2017-03-09 |
| A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03038100) | Hoffmann-La Roche | 2017-03-08 |
| Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer. (NCT04122937) | University of Pisa | 2017-03-01 |
| Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (NCT03335241) | Sun Yat-sen University | 2017-03-01 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer (NCT03042702) | Innovation Pharmaceuticals, Inc. | 2017-02-09 |
| Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT02948426) | National Cancer Institute (NCI) | 2017-02-08 |
| The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors (NCT03507543) | Impact Therapeutics, Inc. | 2017-02-03 |
| Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer (NCT03028519) | University of Oklahoma | 2017-01-31 |
| Cost Utility of Radical Surgery in Ovarian Cancer (NCT02854215) | Institut Claudius Regaud | 2017-01-18 |
| Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (NCT03017573) | Institut Curie | 2017-01-06 |
| Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria (NCT06253559) | Latakia University | 2017-01-01 |
| Long Term Survivors in Ovarian Cancer (NCT03128294) | University Medical Center Groningen | 2017-01-01 |
| Carboplatin-cyclophosphamide Combined With Atezolizumab (NCT02914470) | The Netherlands Cancer Institute | 2017-01-01 |
| FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study (NCT02984423) | AstraZeneca | 2016-12-27 |
| Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors (NCT02988817) | Genmab | 2016-11-23 |
| Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (NCT02884648) | M.D. Anderson Cancer Center | 2016-11-15 |
| A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962) | Dana-Farber Cancer Institute | 2016-11-10 |
| Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma (NCT02933073) | UConn Health | 2016-11-01 |
| Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans (NCT02970786) | Rigshospitalet, Denmark | 2016-11-01 |
| A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis (NCT02475772) | Clemens Tempfer | 2016-11-01 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (NCT02897375) | Emory University | 2016-10-24 |
| Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer (NCT02973750) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-20 |
| A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer (NCT02836028) | Pfizer | 2016-10-01 |
| Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer (NCT02766582) | Medical College of Wisconsin | 2016-10-01 |
| Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making (NCT02916875) | Vejle Hospital | 2016-10-01 |
| Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) (NCT02704832) | Institut Bergonié | 2016-09-30 |